NASDAQ:SPRO Spero Therapeutics (SPRO) Stock Price, News & Analysis $2.69 +0.06 (+2.28%) Closing price 04:00 PM EasternExtended Trading$2.68 0.00 (-0.19%) As of 04:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Spero Therapeutics Stock (NASDAQ:SPRO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Spero Therapeutics alerts:Sign Up Key Stats Today's Range$2.56▼$2.7150-Day Range$2.24▼$2.8652-Week Range$0.66▼$3.22Volume433,185 shsAverage Volume388,995 shsMarket Capitalization$155.75 millionP/E Ratio11.21Dividend YieldN/APrice TargetN/AConsensus RatingReduce Company Overview Spero Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug‐resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges. The company’s lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram‐negative pathogens. In parallel, Spero is advancing SPR720, an oral investigational agent targeting nontuberculous mycobacterial lung infections, and SPR206, a polymyxin derivative intended for intravenous use against a broad spectrum of Gram‐negative bacteria. Together, these programs seek to offer new options where few effective treatments currently exist. Spero conducts clinical trials in North America and internationally, collaborating with academic institutions, hospitals and health authorities to evaluate safety and efficacy across diverse patient populations. The company’s efforts are supported by partnerships with research organizations and regulatory agencies, reflecting a commitment to global health initiatives aimed at reducing the burden of antimicrobial resistance. Under the leadership of President and Chief Executive Officer Ankit Mahadevia, M.D., Spero Therapeutics leverages experience in infectious disease drug development and regulatory strategy. The management team and board of directors include seasoned professionals from both pharmaceutical and biotechnology industries, guiding the company through late‐stage clinical development and toward potential regulatory approvals and commercialization.AI Generated. May Contain Errors. Read More Spero Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks24th Percentile Overall ScoreSPRO MarketRank™: Spero Therapeutics scored higher than 24% of companies evaluated by MarketBeat, and ranked 712th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.0 / 5Analyst RatingReduce Consensus RatingSpero Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageSpero Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Spero Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Spero Therapeutics is 11.19, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.59.Price to Earnings Ratio vs. SectorThe P/E ratio of Spero Therapeutics is 11.19, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 20.91.Price to Book Value per Share RatioSpero Therapeutics has a P/B Ratio of 2.95. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.16% of the float of Spero Therapeutics has been sold short.Short Interest Ratio / Days to CoverSpero Therapeutics has a short interest ratio ("days to cover") of 3.06, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Spero Therapeutics has recently increased by 59.91%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSpero Therapeutics does not currently pay a dividend.Dividend GrowthSpero Therapeutics does not have a long track record of dividend growth. News and Social Media2.3 / 5News SentimentN/A News SentimentSpero Therapeutics has a news sentiment score of -0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Spero Therapeutics this week, compared to 1 article on an average week.Search Interest1 people have searched for SPRO on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Spero Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Spero Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $63,352.00 in company stock.Percentage Held by Insiders5.50% of the stock of Spero Therapeutics is held by insiders.Percentage Held by Institutions25.60% of the stock of Spero Therapeutics is held by institutions.Read more about Spero Therapeutics' insider trading history. Receive SPRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Spero Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SPRO Stock News HeadlinesSpero Therapeutics (NASDAQ:SPRO) Lowered to Hold Rating by Wall Street ZenMay 16, 2026 | americanbankingnews.comSpero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business UpdateMay 13, 2026 | globenewswire.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.May 21 at 1:00 AM | Banyan Hill Publishing (Ad)Spero Therapeutics (SPRO) Expected to Announce Quarterly Earnings on WednesdayMay 11, 2026 | americanbankingnews.comEsther Rajavelu Sells 25,240 Shares of Spero Therapeutics (NASDAQ:SPRO) StockMay 7, 2026 | insidertrades.comSpero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026May 5, 2026 | globenewswire.comSpero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business UpdateMarch 26, 2026 | globenewswire.comSpero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026March 18, 2026 | globenewswire.comSee More Headlines SPRO Stock Analysis - Frequently Asked Questions How have SPRO shares performed this year? Spero Therapeutics' stock was trading at $2.33 at the beginning of the year. Since then, SPRO shares have increased by 15.2% and is now trading at $2.6850. How were Spero Therapeutics' earnings last quarter? Spero Therapeutics, Inc. (NASDAQ:SPRO) posted its quarterly earnings data on Wednesday, May, 13th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.05. The firm had revenue of $0.26 million for the quarter, compared to the consensus estimate of $0.26 million. Spero Therapeutics had a trailing twelve-month return on equity of 35.58% and a net margin of 24.90%. When did Spero Therapeutics IPO? Spero Therapeutics (SPRO) raised $82 million in an IPO on Thursday, November 2nd 2017. The company issued 5,500,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel acted as the underwriters for the IPO and Oppenheimer & Co. was co-manager. Who are Spero Therapeutics' major shareholders? Spero Therapeutics' top institutional investors include Renaissance Technologies LLC (2.05%), Anson Funds Management LP (0.73%) and OMERS ADMINISTRATION Corp (0.07%). Insiders that own company stock include Sath Shukla, Esther Rajavelu, Ankit Mahadevia, Kamal Hamed and Timothy Keutzer. View institutional ownership trends. How do I buy shares of Spero Therapeutics? Shares of SPRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Spero Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Spero Therapeutics investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), Meta Platforms (META), NVIDIA (NVDA), Editas Medicine (EDIT) and Advanced Micro Devices (AMD). Company Calendar Last Earnings5/13/2026Today5/21/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 SPRO's financial health is in the Green zone, according to TradeSmith. SPRO has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SPRO CIK1701108 Websperotherapeutics.com Phone(857) 242-1600FaxN/AEmployees150Year Founded2013Profitability EPS (Trailing Twelve Months)$0.24 Trailing P/E Ratio11.21 Forward P/E RatioN/A P/E GrowthN/ANet Income$8.57 million Net Margins24.90% Pretax Margin25.33% Return on Equity35.58% Return on Assets24.95% Debt Debt-to-Equity RatioN/A Current Ratio10.50 Quick Ratio10.50 Sales & Book Value Annual Sales$66.80 million Price / Sales2.33 Cash Flow$0.16 per share Price / Cash Flow17.02 Book Value$0.91 per share Price / Book2.96Miscellaneous Outstanding Shares57,900,000Free Float54,716,000Market Cap$155.75 million OptionableOptionable Beta1.43 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:SPRO) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
